What does this research mean for the field?

Cytoreductive radical prostatectomy improves survival outcomes, including radiographic progression-free survival and overall survival, in patients with metastatic hormone-sensitive prostate cancer (including high-volume disease) who achieve a deep biochemical response to systemic therapy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study investigates the feasibility and outcomes of cytoreductive radical prostatectomy in high-volume metastatic prostate cancer patients who achieve a deep biochemical response.

June 2, 2026BMC MedicineOpen Access

Cytoreductive radical prostatectomy in patients with high-volume metastatic prostate cancer achieving deep biochemical response to contemporary systemic therapy: a multicentre, prospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

CHCong Huang HGHeng Guo WGWenzhi Gao

Discussion

Member takes

Overview

Prospective cohort study finds cytoreductive surgery improves survival in high-volume metastatic prostate cancer patients.

Key Points

This study investigates the feasibility and outcomes of cytoreductive radical prostatectomy in high-volume metastatic prostate cancer patients who achieve a deep biochemical response.
Multicentre, prospective cohort study conducted from September 2018 to October 2023.
Encouraged lifelong androgen deprivation therapy combined with novel androgen receptor pathway inhibitors.
Primary endpoint was radiographic progression-free survival, analyzed using Cox proportional hazards models.
CRP + standard of care group (n=62) demonstrated longer rPFS (HR 0.36, p=0.035) and OS (HR 0.10, p=0.006) compared to SOC alone (n=64).
In high-volume disease, CRP + SOC improved rPFS (HR 0.31, p=0.036) and PSA-PFS (HR 0.25, p=0.009) after propensity score matching.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6a1e726230b38c64201b5a66 https://doi.org/10.1186/s12916-026-04961-2

View Full Paper

Ask AI

Bookmark

June 2, 2026BMC MedicineOpen Access

Cytoreductive radical prostatectomy in patients with high-volume metastatic prostate cancer achieving deep biochemical response to contemporary systemic therapy: a multicentre, prospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

CHCong Huang HGHeng Guo WGWenzhi Gao

Discussion

Member takes

Overview

Prospective cohort study finds cytoreductive surgery improves survival in high-volume metastatic prostate cancer patients.

Key Points

This study investigates the feasibility and outcomes of cytoreductive radical prostatectomy in high-volume metastatic prostate cancer patients who achieve a deep biochemical response.
Multicentre, prospective cohort study conducted from September 2018 to October 2023.
Encouraged lifelong androgen deprivation therapy combined with novel androgen receptor pathway inhibitors.
Primary endpoint was radiographic progression-free survival, analyzed using Cox proportional hazards models.
CRP + standard of care group (n=62) demonstrated longer rPFS (HR 0.36, p=0.035) and OS (HR 0.10, p=0.006) compared to SOC alone (n=64).
In high-volume disease, CRP + SOC improved rPFS (HR 0.31, p=0.036) and PSA-PFS (HR 0.25, p=0.009) after propensity score matching.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6a1e726230b38c64201b5a66 https://doi.org/10.1186/s12916-026-04961-2

View Full Paper

Ask AI

Bookmark